The DOI matches its Crossref record.
Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our results by hormone receptor status are consistent with previous studies on incidence trends.8,26,27”
From Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status (2024) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 32
- Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23 · doi:10.3233/bd-2006-22103
- Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
- Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21:2254–2259 · DOI
- Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975 · DOI · Paper page
- Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82:2366–2372 · DOI · Paper page
- Goldner B, Behrendt CE, Schoellhammer HF, Lee B, Chen SL (2014) Incidence of inflammatory breast cancer in women, 1992–2009, United States. Ann Surg Oncol 21:1267–1270 · doi:10.1245/s10434-013-3439-y
- Hou N, Huo D (2013) A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat 138:633–641 · DOI
- Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD (2013) What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. RadioGraphics 33:2003–2017 · doi:10.1148/rg.337135503
- Beahrs OH, Carr DT, Rubin P (eds) (1977) Manual for staging of cancer, 1st edn. American Joint Committee for Cancer Staging and End Results Reporting, Chicago
- Beahrs OH, Myers MH (eds) (1983) Manual for staging of cancer, 2nd edn. J.B. Lippincott, Philadelphia
- Beahrs OH, Henson DE, Hutter RV, Myers MH (eds) (1988) Manual for staging of cancer, 3rd edn. J.B. Lippincott, Philadelphia
- Beahrs OH, Henson DE, Hutter RV, Kennedy BJ (eds) (1992) Manual for staging of cancer, 4th edn. J.B. Lippincott, Philadelphia
- Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP et al (eds) (1997) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia
- Shambaugh EM, Gloeckler Ries L, Young JL, Kruse MA, Platz CE, Ryan RF et al (1988) SEER extent of disease 1988 codes and coding instructions. NIH, National Cancer Institute, Rockville
- Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York
- International Agency for Research on Cancer. Geneva: Classification of diseases for oncology, 3rd Edition (ICD-O-3); c2017 [cited 2017 Jan 5]. http://codes.iarc.fr/
- Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116(11 Suppl):2745–2747 · doi:10.1002/cncr.25174
- Chen T, Zhang N, Moran MS, Su P, Haffty BG, Yang Q. Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis (2017). Clinical Breast Cancer 18(1):1–8 · DOI · Paper page
- Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103:1397–1402 · DOI · Paper page
- Howlander N, Chen VW, Ries LAG, Loch MM, Lee R, deSantis C, Lin CC, Ruhl J, Cronin KA (2014) Overview of breast cancer collaborative stage data items – their definitions, quality, usage, and clinical implications: a review of SEER data for 2004–2010. Cancer 120(23 suppl):3771–3780 · DOI
- Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351 (correction: 2001;20:655) · DOI · Paper page
- Devesa SS, Donaldson J, Fears T (1995) Graphical representation of trends in rates. Am J Epidemiol 141:300–304 · DOI · Paper page
- Toriola AT, Colditz GA (2013) Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat 138:665–673 · DOI
- Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72(2):107–115 · DOI · Paper page
- Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epideiol Biomark Prev 13(10):1558–1568 · DOI · Paper page
- Li CI, Beaber EF, Chen Tang M-T, Porter PL, Daling JR, Malone KE (2013) Reproductive factors and risk of estrogen receptor positive, triple negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat 137:579–587 · DOI
- Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DS, Kerlikowske K, Onega TL, Anderson WF, Miglioretti DL (2013) Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst 105:1373–1384 · DOI
- Finer LB, Philbin JM (2014) Trends in ages at key reproductive transitions in the United States, 1951–2010. Women’s Health Issues 24(3):e271–e279 · DOI
- Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114–136 · DOI · Paper page
- An R, Xiang X (2016) Age-period-cohort analyses of obesity prevalence in US adults. Public Health 141:163–169 · DOI
- Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA (2017) Diabetes, abnormal glucose, dyslipidemia, hypertension and risk of inflammatory and other breast cancer. Cancer Epidemiol Biomark Prev 26:862–868 · DOI
- Menke A, Rust KF, Fradkin J, Cheng YJ. Cowie CC (2014) Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States. Ann Intern Med 161:328–335 · DOI
Cited by
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.53331 · Cited by 178
Metadata
- Authors
- Aurit, S. J., Devesa, S. S., Soliman, A. S., & Schairer, C.
- ORCID
- Schairer, Catherine
- Venue
- Breast Cancer Research and Treatment
- Published
- 2019-03-26
- Volume
- 175
- Issue
- 3
- Pages
- 755-764
- ISSN
- 0167-6806
- 1573-7217
- Cited by
- 7
- References
- 0
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- Funders
- Division of Cancer Prevention, National Cancer Institute (R25 CA112383)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015). https://app.cochat.ai/papers/10.1007/s10549-019-05193-0
- The paper
- Aurit, S. J., Devesa, S. S., Soliman, A. S., & Schairer, C. (2019). Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05193-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.